Previous Investigations
Other Litigations Trasylol Research Center
|
Weitz & Luxenberg is no longer accepting Trasylol cases
FREE information from a Trasylol lawyer: FDA Issues Public Health Advisory for Trasylol.
Trasylol, known generically as aprotinin, was used to control bleeding in hundreds of thousands of heart-bypass patients since the Food and Drug Administration (FDA) approved it in 1993.
Bayer AG, marketer of the drug, was forced to pull it from the market last year, after researchers linked it to serious side effects like kidney failure, heart attacks, and strokes.
Some who have been harmed by the pharmaceutical have begun to seek out our Drug and Medical Device lawyers.
Two studies published in the February 2008 issue of the New England Journal of Medicine support earlier finding that the drug is unsafe.
Research studies have linked Trasylol to an increased risk of:
If you experienced complications after surgery, be in touch with your physician to determine if Trasylol was used during the procedure. Please complete the form below for more information from a Trasylol lawyer. A representative of our firm will contact you as soon as possible.
see also:
FDA Trasylol Statement
FDA Statement Regarding Bayer's New Trasylol Data--Free legal infoFDA: Bayer's Trasylol Data from two research studies--Lawsuit Review
FDA Advisory
Were You Given Trasylol (Aprotinin)? Get FDA Information on the RisksAlert for Trasylol (Aprotinin) - FDA Issues Public Health Advisory
Trasylol News
Updated News on the Harmful Health Risks Associated with TrasylolGet Trasylol news and a free legal review of your case from a lawyer
